70% of mice eliminate pancreatic cancer!

Pancreatic ductal adenocarcinoma (PDAC), often referred to as the "king of cancer", is the most common type of pancreatic cancer and one of the most dangerous cancers in various solid tumors

Chemotherapy, immunotherapy, etc.

However, a few days ago, the top academic journal "Cell" published an exciting study, which is expected to change the difficult situation of pancreatic cancer treatment

Leading this research is Professor Lu Kunping and Professor Zhou Xiaozhen, Chinese scientists at Harvard Medical School

In this study, the team found that Pin1 was overexpressed in cancer cells and cancer-related fibroblasts of patients with pancreatic ductal adenocarcinoma, and that the high expression of Pin1 was related to the poor survival rate of patients

Experimental results show that in a variety of pancreatic cancer model mice, the use of clinically developed Pin1 inhibitors, with immunotherapy PD-1 inhibitors and chemotherapy drugs gemcitabine (gemcitabine), can completely eliminate or continue to relieve mice Tumor in the body!

In pancreatic cancer mice introduced with two oncogenes Kras and p53 mutations, if only gemcitabine and PD-1 inhibitors were used, the effect was minimal, and most of the mice died within 3 months; however, Pin1 inhibitors were added The treatment significantly improved the survival rate.

▲Schematic diagram of Pin1 inhibitors, immunotherapy, and chemotherapy to eradicate pancreatic cancer (picture source: reference [1])

As to why Pin1 inhibitors can significantly enhance the effect of immunochemotherapy, the research team also analyzed the underlying mechanism

Note: The original text has been deleted

Reference

[1] Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.